Interventional Glaucoma Business Manager
Glaukos
Interventional Glaucoma Business Manager
Glaukos
Medical devices for glaucoma treatment
The Interventional Glaucoma Business Manager (iGBM) plays a critical role in driving the adoption and integration of Glaukos technologies within ophthalmic surgical practices. This individual will achieve quarterly sales objectives by engaging targeted ophthalmic surgeons, providing clinical support during procedures, and delivering hands-on training to ensure optimal patient outcomes. The IGBM manages the territory strategically, focusing on customer success, business growth, and long-term partnership development.
How will you make an impact?
The Interventional Glaucoma Business Manager (iGBM) plays a critical role in driving the adoption and integration of Glaukos technologies within ophthalmic surgical practices. This individual will achieve quarterly sales objectives by engaging targeted ophthalmic surgeons, providing clinical support during procedures, and delivering hands-on training to ensure optimal patient outcomes. The IGBM manages the territory strategically, focusing on customer success, business growth, and long-term partnership development.
What will you do?
Sales Strategy & Execution
Clinical Integration & Support
Customer Engagement & Education
Market Development & Events
How will you get here?
*Total Targeted Compensation $285k+ plus RSU's.
#GKOSUS
#LI-remote
Job Salary Range: 150,000 - 150,000
Glaukos focuses on ophthalmology by developing and commercializing medical devices and therapies for glaucoma, corneal disorders, and retinal diseases. Its products mainly target surgeons who treat eye conditions, with a core technology in micro invasive glaucoma surgery (MIGS). The company’s MIGS devices, such as the Trabecular Micro Bypass Stent and next-generation iStent, are implanted in the eye to improve outflow of eye fluid and lower intraocular pressure, offering a less invasive option compared with traditional surgeries. Glaukos differentiates itself by pioneering MIGS and bringing the first US-approved MIGS device to market in 2012, continuing to expand its portfolio through research, development, and strategic acquisitions. The company aims to improve patient care by providing safer, effective, and longer-lasting treatment options for glaucoma and related eye diseases, addressing unmet needs in ophthalmology.
Explore more opportunities at Glaukos